Q-linea AB (SE:QLINEA)
:QLINEA
Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr29.00
>-kr0.01(-3.85%)
At close: 4:00 PM EST
kr29.00
>-kr0.01(-3.85%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr74.06
Previous CloseN/A
Volume6.05M
Average Volume (3M)13.43K
Market Cap
kr314.69M
Enterprise Value-kr107.21M
Total Cash (Recent Filing)kr223.91M
Total Debt (Recent Filing)kr4.15M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.75
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Recurring Razor-and-blades ModelThe instrument-plus-consumables model creates a durable revenue stream as installed instruments drive recurring test sales. Over months this supports predictable revenue scaling and margin improvement potential if instrument placements and test utilization increase, aligning incentives for customer retention.
Low Leverage And Restored EquityA modest debt load and restored positive equity provide financial flexibility to invest in commercialization and R&D without immediate solvency pressure. This balance-sheet strength reduces bankruptcy risk and improves access to capital during a multi-quarter scaling phase or selective fundraising events.
Structural Demand For Rapid DiagnosticsHospitals and clinical labs have a durable need for faster pathogen ID and antimicrobial susceptibility testing. Q-linea's automated platform targets that structural market need, supporting long-term adoption potential and recurring consumable sales as health systems prioritize faster clinical decision-making.
Bears Say
High Cash BurnVery large negative operating and free cash flows create an ongoing funding requirement that pressures runway and forces external financing or dilution. Over a multi-month horizon this constrains investment flexibility and could delay commercialization or scaling if additional capital is not secured.
Small, Declining Revenue BaseA tiny and shrinking revenue base with negative gross profit indicates weak unit economics and limited operating leverage. Without meaningful revenue scale or improved margins, the business lacks internal cash generation, making sustained growth and profitable scale challenging over the coming quarters.
Large Ongoing Losses And Negative ReturnsPersistent, sizeable losses reflected in negative ROE signal a long path to profitability and continued value erosion absent turnaround. This long-term earnings weakness raises execution risk, pressures investor support, and magnifies the impact of further operational setbacks over months.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr74.06 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr314.69M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Jul 10, 2026 which is in 47 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Apr 30, 2026. The company reported -kr1.772 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.772.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.772 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.371%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―